scholarly journals IMPACT OF ARTIFICIAL LIVER SUPPORT WITH ALBUMIN DIALYSIS (MARS) ON LABORATORY FINDINGS

ASAIO Journal ◽  
2000 ◽  
Vol 46 (2) ◽  
pp. 242
Author(s):  
S. Klammt ◽  
S. Mitzner ◽  
J. Stange ◽  
B. Brinkmann ◽  
P. Peszynski ◽  
...  
Keyword(s):  
Artificial Liver ◽  
Albumin Dialysis ◽  
Liver Support ◽  
Laboratory Findings ◽  
Artificial Liver Support

Albumin Dialysis With a Noncell Artificial Liver Support Device in Patients With Acute Liver Failure

2013 ◽  
Vol 159 (8) ◽  
pp. 522 ◽  
Author(s):  
Faouzi Saliba ◽  
Christophe Camus ◽  
François Durand ◽  
Philippe Mathurin ◽  
Alexia Letierce ◽  
...  
Keyword(s):  
Liver Failure ◽  
Acute Liver Failure ◽  
Artificial Liver ◽  
Albumin Dialysis ◽  
Liver Support ◽  
Artificial Liver Support ◽  
Support Device

The Comparison of Albumin Dialysis between Open- and Closed-Loop Dialysis Modes

2014 ◽  
Vol 960-961 ◽  
pp. 47-51
Author(s):  
Ying Ying Pei ◽  
Yi Ze Sun ◽  
Si Jie Sun ◽  
Da Yong Gao ◽  
Wei Ping Ding
Keyword(s):  
Closed Loop ◽  
Support Systems ◽  
Open Loop ◽  
Molar Ratio ◽  
Artificial Liver ◽  
Albumin Dialysis ◽  
Liver Support ◽  
Artificial Liver Support ◽  
Physical Size ◽  
Overall Performance

The open-loop albumin dialysis mode (OLM) is usually used to remove protein-bound toxins from artificial liver support systems. However, there is still interest in closed-loop albumin dialysis mode (CLM) because this mode could enable the regeneration and reuse of albumin and minimize the physical size of liver support systems. In this paper, the two dialysis modes were theoretically compared under various theoretical conditions. Our results show that at the beginning of the dialysis period, in terms of detoxification efficiency, CLM is better. As the molar ratio of toxin to albumin in the blood (RTA) decreases, the overall performance of CLM approaches that of OLM in 4-hour dialysis. In certain cases, the clearance of albumin-bound toxins by CLM could be as effective as that by OLM; occasionally, CLM is even more effective.

Changes of laboratory findings in artificial liver support by albumindialysis (MARS)

2000 ◽  
Vol 32 ◽  
pp. 73
Author(s):  
S. Klammt ◽  
S. Mitzner ◽  
J. Stange ◽  
P. Peszynski ◽  
J. Loock ◽  
...  
Keyword(s):  
Artificial Liver ◽  
Liver Support ◽  
Laboratory Findings ◽  
Artificial Liver Support

Albumin Dialysis in Artificial Liver Support Systems

ASAIO Journal ◽  
2015 ◽  
Vol 61 (3) ◽  
pp. 324-331
Author(s):  
Yingying Pei ◽  
Yize Sun ◽  
Sijie Sun ◽  
Dayong Gao ◽  
Weiping Ding
Keyword(s):  
Support Systems ◽  
Artificial Liver ◽  
Albumin Dialysis ◽  
Liver Support ◽  
Artificial Liver Support

scholarly journals Successful elimination of bilirubin in critically ill patients with acute liver dysfunction using a cytokine adsorber and albumin dialysis: a pilot study

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Christina Scharf ◽  
Uwe Liebchen ◽  
Michael Paal ◽  
Andrea Becker-Pennrich ◽  
Michael Irlbeck ◽  
...  
Keyword(s):  
Liver Dysfunction ◽  
Total Bilirubin ◽  
Wilcoxon Test ◽  
Organ Support ◽  
Relative Reduction ◽  
High Flux ◽  
Albumin Dialysis ◽  
Liver Support ◽  
Artificial Liver Support ◽  
Significant Difference

AbstractThere are different methods of artificial liver support for patients with acute liver dysfunction (ALD). However, CytoSorb (CS) might be a new approved option for those patients. Question of interest is whether the elimination performance of CS was comparable to that of advanced organ support (ADVOS). Patients, treated with CS (integrated into high-flux dialysis) or ADVOS and a total bilirubin > 10 mg/dl were included. Laboratory parameters were evaluated before starting therapy (d0) and 12–24 h thereafter (d1). The Wilcoxon-test with associated samples was used for statistical analysis. Thirty-nine patients (33 CS, 6 ADVOS) were included. The median bilirubin at d0 was 16.9 and 17.7 mg/dl and at d1 was 13.2 and 15.9 mg/dl, in the CS and ADVOS group, respectively. There was a significant bilirubin reduction as well in the CS group (p < 0.001, median relative reduction: 22.5%) as in the ADVOS group (p = 0.028, median relative reduction: 22.8%). There was no significant difference in the relative bilirubin reduction between CS and ADVOS therapies. The use of CytoSorb and ADVOS in patients with ALD led to a significant and comparable decrease in total bilirubin. The easy use of CS might be an advantage compared to other procedures.

Sign in / Sign up

Export Citation Format

Share Document